Abstract 29P
Background
Breast cancer is the most common type of cancer for women worldwide and in Indonesia. Breast cancer patients in Bali, especially in Denpasar, are mostly diagnosed during advanced stage. Among those late stage diagnosis, 40-50 years old being the most prevalent with young women (<40 years old) being above average in prevalence. Early detection such as Breast Self Examination (BSE) is very crucial to prevent late stage detection. Therefore, we aimed to evaluate factors affecting BSE behavior among female high school students in Denpasar City, Bali Province, Indonesia.
Methods
A pre-experimental cross-sectional study-based community was conduct on 11 January 2020 in Denpasar, Bali. The data is collected using a validated questionnaires to evaluate knowledge, attitude, behavior, information exposure, parent support, and peer support as factors affecting BSE behavior among female high school students. Data is analyzed using chi-square with p-value ≤0.05 is categorized as significant.
Results
82 respondents were involved in this study with a mean age of 15.93 ± 0,798 years. Mostly the students have high knowledge (63.4%), good attitude towards BSE (51.2%), BSE information exposed (58.5%), low parent support towards BSE (57.3%), and low peer support towards BSE (74.4%). The highest significant factor is knowledge (p= 0.001, OR=6.500), followed by BSE information exposed (p=0.003, OR=4.667), and peer support (p=0.023, OR=3.185).
Conclusions
We conclude that factors affecting BSE behavior among female high school students in Denpasar, Bali are knowledge, BSE information exposed, and peer support. We suggest greater attention in improving students’ knowledge, expose more information about BSE, and educate peer support towards BSE among female high school students in Denpasar, Bali.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Badan Semi Otonom Komunitas Mahasiswa Peduli Kanker Fakultas Kedokteran Universitas Udayana.
Funding
Badan Semi Otonom Komunitas Mahasiswa Peduli Kanker Fakultas Kedokteran Universitas Udayana.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session